Details for Patent: 12,116,368
✉ Email this page to a colleague
Which drugs does patent 12,116,368 protect, and when does it expire?
Patent 12,116,368 protects LITFULO and is included in one NDA.
This patent has seventeen patent family members in fourteen countries.
Drugs Protected by US Patent 12,116,368
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | LITFULO | ritlecitinib tosylate | CAPSULE;ORAL | 215830-001 | Jun 23, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,116,368
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 116797 | ⤷ Subscribe | |||
Australia | 2019363840 | ⤷ Subscribe | |||
Brazil | 112021007568 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |